Financials GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:16 2024-11-29 am EST			5-day change	1st Jan Change
1,335.00 ^GBX	-0.41%		-0.52%	-7.94%

Nov. 29	Wall Street hit by turkey coma
Nov. 29	Intron Health Downgrades GSK to Sell, Cuts PT	MT

Projected Income Statement: GSK plc

income-statement-evolution-chart GSK-PLC

Fiscal Period: Dicembre	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	33,754	34,099	34,114	29,324	30,328	31,191	32,340	34,249
Change	-	1.02%	0.04%	-14.04%	3.42%	2.85%	3.68%	5.9%
EBITDA ¹	11,968	9,530	11,330	10,449	11,635	10,291	11,267	12,425
Change	-	-20.37%	18.89%	-7.78%	11.35%	-11.55%	9.48%	10.27%
EBIT ¹	8,972	8,906	8,806	8,151	8,786	9,011	9,560	10,636
Change	-	-0.74%	-1.12%	-7.44%	7.79%	2.56%	6.09%	11.25%
Interest Paid ¹	-814	-848	-756	-803	-677	-581.3	-576.5	-542.6
Earnings before Tax (EBT) ¹	6,221	6,968	5,442	5,628	6,064	4,203	7,873	9,071
Change	-	12.01%	-21.9%	3.42%	7.75%	-30.69%	87.31%	15.21%
Net income ¹	4,645	5,749	4,385	14,956	4,928	3,726	5,845	6,547
Change	-	23.77%	-23.73%	241.07%	-67.05%	-24.4%	56.9%	11.99%
Announcement Date	2/5/20	2/3/21	2/9/22	2/1/23	1/31/24	-	-	-

¹GBP in Million

Estimates

Fiscal Period: December	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	8,899	9,090	7,624	8,646	8,739	7,418	8,092	9,077	9,527	9,780	6,929	7,829	7,376	6,951	7,178	8,147	8,052	7,363	7,884	8,012	7,644	-	-	-	-
Change	-	2.15%	-16.13%	13.41%	1.08%	-15.12%	9.09%	12.17%	4.96%	2.66%	-29.15%	12.99%	-5.79%	-5.76%	3.27%	13.5%	-1.17%	-8.56%	7.08%	1.62%	-4.59%	-100%	-	-	-
EBITDA ¹	2,376	2,869	2,526	2,024	2,111	2,041	2,822	3,860	2,406	3,317	2,639	3,561	1,602	2,732	2,622	3,351	2,930	2,992	3,152	3,712	1,731	-	-	-	-
Change	-	20.75%	-11.96%	-19.87%	4.3%	-3.32%	38.27%	36.78%	-37.67%	37.86%	-20.44%	34.94%	-55.01%	70.54%	-4.03%	27.8%	-12.56%	2.12%	5.35%	17.77%	-53.37%	-100%	-	-	-
EBIT ¹	1,852	2,675	1,749	2,665	1,817	1,881	2,158	2,874	1,893	2,613	2,008	2,605	1,595	2,092	2,170	2,772	1,752	2,443	2,513	2,761	1,347	-	-	-	-
Change	-	44.44%	-34.62%	52.37%	-31.82%	3.52%	14.73%	33.18%	-34.13%	38.03%	-23.15%	29.73%	-38.77%	31.16%	3.73%	27.74%	-36.8%	39.44%	2.87%	9.87%	-51.2%	-100%	-	-	-
Charge d'intérêts ¹	-195	-188	-227	-198	-234	-191	-185	-193	-187	-202	-183	-177	-244	-174	-152	-158	-193	-134	-150	-124	-158	-115	-130	-130	-160
Earnings before Tax (EBT) ¹	1,711	1,835	2,641	1,671	821	1,518	1,470	1,748	706	2,598	896	1,012	1,626	1,907	1,987	1,791	379	1,355	1,495	64	948	-	-	-	-
Change	-	7.25%	43.92%	-36.73%	-50.87%	84.9%	-3.16%	18.91%	-59.61%	267.99%	-65.51%	12.95%	60.67%	17.28%	4.2%	-9.86%	-78.84%	257.52%	10.33%	-95.72%	1,381.25%	-100%	-	-	-
Net income ¹	1,299	1,565	2,263	1,244	677	1,073	1,395	1,168	749	1,802	975	10,315	1,495	1,490	1,624	1,464	350	1,046	1,173	-58	801.5	-	-	-	-
Change	-	20.48%	44.6%	-45.03%	-45.58%	58.49%	30.01%	-16.27%	-35.87%	140.59%	-45.89%	957.95%	-85.51%	-0.33%	8.99%	-9.85%	-76.09%	198.86%	12.14%	-	-	-100%	-	-	-
Announcement Date	2/5/20	4/29/20	7/29/20	10/28/20	2/3/21	4/28/21	7/28/21	10/27/21	2/9/22	4/27/22	7/27/22	11/2/22	2/1/23	4/26/23	7/26/23	11/1/23	1/31/24	5/1/24	7/31/24	10/30/24	-	-	-	-	-

¹GBP in Million

Estimates

Forecast Balance Sheet: GSK plc

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	25,722	20,780	19,838	17,197	15,040	13,521	11,301	8,134
Change	-	-19.21%	-4.53%	-13.31%	-12.54%	-10.1%	-16.42%	-28.02%
Announcement Date	2/5/20	2/3/21	2/9/22	2/1/23	1/31/24	-	-	-

¹GBP in Million

Estimates

Cash Flow Forecast: GSK plc

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	1,265	1,226	1,172	1,143	1,314	1,455	1,506	1,596
Change	-	-3.08%	-4.4%	-2.47%	14.96%	10.76%	3.49%	5.95%
Free Cash Flow (FCF) ¹	5,073	5,406	4,437	6,260	5,454	3,962	5,457	6,457
Change	-	6.56%	-17.92%	41.09%	-12.88%	-27.35%	37.71%	18.34%
Announcement Date	2/5/20	2/3/21	2/9/22	2/1/23	1/31/24	-	-	-

¹GBP in Million

Estimates

Forecast Financial Ratios: GSK plc

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	35.46%	27.95%	33.21%	35.63%	38.36%	32.99%	34.84%	36.28%
EBIT Margin (%)	26.58%	26.12%	25.81%	27.8%	28.97%	28.89%	29.56%	31.05%
EBT Margin (%)	18.43%	20.43%	15.95%	19.19%	19.99%	13.48%	24.35%	26.49%
Net margin (%)	13.76%	16.86%	12.85%	51%	16.25%	11.94%	18.08%	19.11%
FCF margin (%)	15.03%	15.85%	13.01%	21.35%	17.98%	12.7%	16.87%	18.85%
FCF / Net Income (%)	109.21%	94.03%	101.19%	41.86%	110.67%	106.35%	93.35%	98.63%
Profitability
ROA	8.9%	7.18%	5.5%	8.08%	10.55%	7.99%	10.58%	11.19%
ROE	75.02%	44.39%	38.22%	43.85%	52.48%	44.28%	40.36%	38.53%
Financial Health
Leverage (Debt/EBITDA)	2.15x	2.18x	1.75x	1.65x	1.29x	1.31x	1x	0.65x
Debt / Free cash flow	5.07x	3.84x	4.47x	2.75x	2.76x	3.41x	2.07x	1.26x
Capital Intensity
CAPEX / Current Assets (%)	3.75%	3.6%	3.44%	3.9%	4.33%	4.67%	4.66%	4.66%
CAPEX / EBITDA (%)	10.57%	12.86%	10.34%	10.94%	11.29%	14.14%	13.37%	12.84%
CAPEX / FCF (%)	24.94%	22.68%	26.41%	18.26%	24.09%	36.73%	27.6%	24.71%
Items per share
Cash flow per share ¹	1.999	2.094	1.962	1.813	1.67	1.604	1.679	1.888
Change	-	4.79%	-6.3%	-7.63%	-7.86%	-3.98%	4.67%	12.49%
Dividend per Share ¹	1	1	1	0.6125	0.58	0.6031	0.6431	0.6908
Change	-	0%	0%	-38.75%	-5.31%	3.99%	6.63%	7.42%
Book Value Per Share ¹	3.024	3.661	3.758	2.627	3.294	3.689	4.212	5.006
Change	-	21.04%	2.65%	-30.09%	25.38%	11.98%	14.18%	18.86%
EPS ¹	1.158	1.426	1.082	3.662	1.216	0.9119	1.424	1.592
Change	-	23.22%	-24.1%	238.29%	-66.79%	-25.01%	56.15%	11.77%
Nbr of stocks (in thousands)	3,959,572	3,982,185	4,006,383	4,060,999	4,076,145	4,080,500	4,080,500	4,080,500
Announcement Date	2/5/20	2/3/21	2/9/22	2/1/23	1/31/24	-	-	-